Zacks Research upgraded shares of Anika Therapeutics (NASDAQ:ANIK – Free Report) from a hold rating to a strong-buy rating in a research note released on Wednesday morning,Zacks.com reports. Finally, Wall Street Zen raised shares of Anika Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 1st. Get Anika Therapeutics alerts:Check Out Our Latest Stock Analysis on Anika TherapeuticsAnika Therapeutics Price PerformanceAnika Therapeutics stock opened at $20.16 on Wednesday. Anika Therapeutics Company Profile(Get Free Report)Anika Therapeutics, Inc is a life sciences company specializing in the development and commercialization of hyaluronic acid–based therapeutic products. Recommended StoriesReceive News & Ratings for Anika Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anika Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.